Podcast: Play in new window | Download
Subscribe: RSS
Dr. Kevin Spelman returns to discuss what research has been done on the minor cannabinoids. The major cannabinoids, Delta-9 THC and CBD, have gotten most of the attention when it comes to cannabis medicine research. But we know that cannabis medicine is a team effort, and there are a variety of compounds that contribute to the entourage effect, including terpenoids, flavonoids, stilbenoids, and minor cannabinoids.
Kevin has a wealth of knowledge when it comes to medicinal plant, nutraceutical, and cannabinoid research and has authored 29 peer-reviewed publications on medicinal plants. Over the last 30 years, he has coordinated new product development, formulated product lines, and advised on analytical and QC guidelines, research activity, and educational curriculums for industry and universities. Kevin is also an instructor on the CannMed 2022 Medical Practicum.
During our conversation we discuss:
- Most of the research into minor cannabinoids is pre-clinical and in isolation, which means our understanding of how they contribute to the entourage effect is largely unknown
- The different classes of cannabinoids (neutral, acids, and varins)
- How different forms of cannabinoids can sometimes have an opposite effect on cell receptors. For example THCA vs THCV.
- What minor cannabinoids consumers can look for in products
- A recap of what is known about the major, minor cannabinoids (CBG, CBN, CBC, THCA, CBDA, THCV, and CBDV)
Thank You to This Episode’s Sponsor: The Cannigma
The Cannigma is a cannabis education site that’s committed to making sure scientific information about cannabis is accessible to anyone who needs it – be it to relieve their own suffering or that of a loved one, to learn a bit more, or even just for fun. The site takes an evidence-based approach to every issue surrounding cannabis – from safety to cooking to medical research – and makes all of that information digestible and useful.
Learn more at cannigma.com.
Additional Resources